A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Genetics

• Publication date

  2017-08-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ng.3934PMID 28825726PMCID PMC7376751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

  2017cited by this paper
• Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

  2017cited by this paper
• Repair Pathway Choices and Consequences at the Double-Strand Break.

  2016cited by this paper
• BRCAness revisited

  2016cited by this paper
• Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors

  2016cited by this paper
• Landscape of somatic mutations in 560 breast cancer whole genome sequences

  2016cited by this paper
• Risky business: getting a grip on BRIP

  2016cited by this paper
• No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

  2016cited by this paper
• BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

  2016cited by this paper
• Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

  2016cited by this paper
• Hereditary breast and ovarian cancer: new genes in confined pathways

  2016cited by this paper
• PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

  2016cited by this paper
• The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

  2016cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

  2015cited by this paper
• Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

  2015cited by this paper
• Patterns and functional implications of rare germline variants across 12 cancer types

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair

  2015cited by this paper
• Analysis of protein-coding genetic variation in 60,706 humans

  2015cited by this paper
• Whole genomes redefine the mutational landscape of pancreatic cancer

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• PARP inhibitors in BRCA mutation-associated ovarian cancer.

  2015cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cited by this paper
• Gene-panel sequencing and the prediction of breast-cancer risk.

  2015cited by this paper
• Triple-negative breast cancer in African-American women: disparities versus biology

  2015cited by this paper
• BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

  2015cited by this paper
• ClinGen--the Clinical Genome Resource.

  2015cited by this paper
• Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.

  2015cited by this paper
• Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution

  2015cited by this paper
• Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

  2015cited by this paper
• BRCA1 haploinsufficiency for replication stress suppression in primary cells

  2014cited by this paper
• Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014cited by this paper
• RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families

  2014cited by this paper
• Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• ClinVar: public archive of relationships among sequence variation and human phenotype

  2013cited by this paper
• The genomic landscape of breast cancer as a therapeutic roadmap.

  2013cited by this paper
• RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

  2013cited by this paper
• Rescuing stalled or damaged replication forks.

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Germline RAD51C mutations confer susceptibility to ovarian cancer

  2012cited by this paper
• Mutational Processes Molding the Genomes of 21 Breast Cancers

  2012cited by this paper
• A review of a multifactorial probability‐based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)

  2012cited by this paper
• Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

  2012cited by this paper
• ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

  2012cited by this paper
• Germline RAD51C mutations confer susceptibility to ovarian cancer

  2012cited by this paper
• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

  2012cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• PARP inhibition in BRCA-mutated breast and ovarian cancers.

  2010cited by this paper
• RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer

  2010cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Complicated Supercomplexes

  2009cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003influential reference
• The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation*

  2001cited by this paper
• Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

  2000cited by this paper
• In search of the tumour-suppressor functions of BRCA1 and BRCA2

  2000cited by this paper
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families

  1995cited by this paper
• High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium.

  1995cited by this paper
• Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.

  1995cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper

• The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers

  2026cites this paper
• The expanding roles of homologous recombination proteins in genome stability

  2026cites this paper
• Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study

  2026influential citation
• BRCA and CDK4/6: allies or antagonists?—efficacy of CDK4/6 inhibitors in HR+/HER2− breast cancer with germline BRCA1/2 mutations: a narrative review

  2026cites this paper
• TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

  2026cites this paper
• SigFormer: an Attention-Based Framework for Robust Single-Sample Mutational Signature Decomposition

  2026cites this paper
• AlphaMissense for Identifying Pathogenic Missense Mutations in DNA Damage Repair Genes in Cancer

  2025cites this paper
• Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer

  2025cites this paper
• Comprehensive Analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in Melanoma.

  2025cites this paper
• Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

  2025cites this paper
• Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

  2025cites this paper
• Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

  2025cites this paper
• Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer

  2025cites this paper
• Assessing the anticancer potential of Bergenia ciliata conjugated silk fibroin nanoparticles through histopathological and biomarkers study

  2025cites this paper
• The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination

  2025cites this paper
• Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data

  2025cites this paper
• The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer

  2025cites this paper
• Learning the cellular origins across cancers using single-cell chromatin landscapes

  2025cites this paper
• Dissecting the Emerging Regulatory and Mechanistic Paradigms of Transcribed Conserved Non-Coding Elements in Breast Cancer

  2025cites this paper
• Precision proteogenomics reveals pan-cancer impact of germline variants.

  2025cites this paper
• Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment

  2025cites this paper
• Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas

  2025cites this paper
• The challenge of ultra-rare, overlooked cancer predisposition syndromes: unveiling the role of cancer genome profiling

  2025cites this paper
• Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

  2025cites this paper
• Deep Learning for Biomarker Discovery in Cancer Genomes

  2025cites this paper
• Navigating the winding road toward precision prostate cancer care.

  2025cites this paper
• Safety and potential radiosensitizing effect of Olaparib in combination with breast radiotherapy for TNBC patients with residual disease: long-term results from the RADIOPARP Phase I Trial: Safety and Radiosensitization of Olaparib with Radiotherapy in TNBC.

  2025cites this paper
• Analysis of homologous recombination deficiency in prostate cancer

  2025cites this paper
• HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data

  2025cites this paper
• Tissue specificity and chromosomal alterations shape divergent immune programs in HRD tumors

  2025cites this paper
• Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile

  2025cites this paper
• Joint inference of mutational signatures from indels and single-nucleotide substitutions reveals prognostic impact of DNA repair deficiencies

  2025cites this paper
• Case Report: Functional validation of a rare variant BRCA1 c.5193 + 2dupT in a family with cancer history

  2025influential citation
• Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer

  2025cites this paper
• Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer

  2025cites this paper
• ASCC1 structures and bioinformatics reveal a novel helix-clasp-helix RNA-binding motif linked to a two-histidine phosphodiesterase

  2024cites this paper
• Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1/2‐mutated cancer

  2024cites this paper
• Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancers

  2024cites this paper
• Experience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma

  2024cites this paper
• General Applicability of Existing College of American Pathologists Accreditation Requirements to Clinical Implementation of Machine Learning-Based Methods in Molecular Oncology Testing.

  2024cites this paper
• A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.

  2024cites this paper
• Genetic ancestry-specific meQTLs control immune function regulation in a breast cancer cohort of African and European patients

  2024cites this paper
• The treatment landscape of triple-negative breast cancer

  2024influential citation
• Advances in the Understanding of the Pathogenesis of Triple‐Negative Breast Cancer

  2024cites this paper
• Genome sequencing enhances the diagnostic yield and expands the genetic landscape of male breast cancer

  2024cites this paper
• Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides

  2024cites this paper
• Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer

  2024cites this paper
• Tumor analysis of BRCA carriers reveals genomic similarities although separated by time

  2024cites this paper
• Synthetic lethal strategies for the development of cancer therapeutics

  2024cites this paper
• Cosmic signature SBS39 is associated with homologous recombination deficiency

  2024cites this paper
• Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer

  2024influential citation
• BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?

  2024cites this paper
• Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy

  2024cites this paper
• A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

  2024cites this paper
• Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer.

  2024cites this paper
• Impact of genomic and epigenomic alterations of multigene on a multicancer pedigree

  2024cites this paper
• Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency

  2024cites this paper
• BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality

  2024cites this paper
• Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

  2024cites this paper
• Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

  2024cites this paper
• Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification

  2024cites this paper
• On the Hunt for the Missed Genetic Causes of Multiple Primary Tumors.

  2024cites this paper
• The mutagenic consequences of defective DNA repair.

  2024cites this paper
• PARP Inhibitors for Breast Cancer Treatment: A Review.

  2024cites this paper
• Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient

  2024cites this paper
• Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma

  2024cites this paper
• (Single-stranded DNA) gaps in understanding BRCAness.

  2024cites this paper
• Histopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction

  2024cites this paper
• Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast and ovarian cancers

  2024cites this paper
• ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers

  2024cites this paper
• A review on trends in development and translation of omics signatures in cancer

  2024cites this paper
• A deep-learning-based genomic status estimating framework for homologous recombination deficiency detection from low-pass whole genome sequencing

  2024cites this paper
• Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models.

  2024cites this paper
• Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

  2024cites this paper
• Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation.

  2023cites this paper
• Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

  2023cites this paper
• Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer

  2023influential citation
• Genetic and molecular analyses of candidate germline BRIP1/FANCJ variants implicated in breast and ovarian cancer

  2023cites this paper
• Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

  2023cites this paper
• Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. Reply.

  2023cites this paper
• Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors

  2023cites this paper
• ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis)

  2023cites this paper
• Copy number alteration features in pan-cancer homologous recombination deficiency prediction and biology

  2023cites this paper
• FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

  2023cites this paper
• FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer

  2023cites this paper
• A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

  2023cites this paper
• Targeting homologous recombination deficiency in uterine leiomyosarcoma

  2023cites this paper
• Emerging predictive biomarkers in the management of bone and soft tissue sarcomas

  2023cites this paper
• Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma.

  2023cites this paper
• Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

  2023cites this paper
• Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile

  2023cites this paper
• Modeling the relationship between gene expression and mutational signature

  2023cites this paper
• A FAIR platform for reproducing mutational signature detection on tumor sequencing data

  2023cites this paper
• A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score

  2023cites this paper
• Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status

  2023cites this paper
• Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers

  2023cites this paper
• Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer

  2023cites this paper
• BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib

  2023cites this paper
• Analysis of evolutionary dynamics and clonal architecture in prostate cancer

  2023cites this paper
• Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.

  2023cites this paper